Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may predict lung cancer outcomes

NCT ID NCT07316309

Knowledge-focused Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a new type of PET/CT scan can help predict how well treatment will work for people with a certain type of lung cancer (limited-stage small cell lung cancer). 33 participants had the scan before starting standard treatment. Researchers then tracked their cancer progression to see if the scan results could forecast outcomes. The goal is to better understand which patients might need more or less aggressive treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

33 people

The number who actually took part.

Started

Nov 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with newly diagnosed, histopathologically confirmed limited-stage small cell lung cancer who underwent baseline \[18F\]AlF-NOTA-QHY-04 PET/CT imaging prior to concurrent chemoradiotherapy at Shandong Cancer Hospital and Institute.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed limited-stage small cell lung cancer (T1-4N0-3M0) according to the AJCC TNM 8th edition. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Presence of measurable disease according to RECIST version 1.1. * Newly diagnosed patients who had not received any prior anticancer treatment. * Underwent baseline \[18F\]AlF-NOTA-QHY-04 PET/CT imaging prior to treatment. Exclusion Criteria: * Presence of autoimmune diseases or active comorbid infections. * Pregnancy or breastfeeding. * Unable or unwilling to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung cancer

Contacts and locations

Locations

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.